📇 Rhumatologue ·
Chargement de la fiche…
Chargement de la fiche…
MonRhumato.fr utilise des cookies pour mesurer l'audience (statistiques) et améliorer le site. Aucune donnée de santé identifiable n'est jamais collectée. Politique de confidentialité.
Votre choix est conservé 13 mois (durée max CNIL). Vous pouvez le modifier à tout moment via Préférences cookies.
1 raison identifiée
Praticien-chercheur
5 articles scientifiques publiés — formation continue solide
✨ Génération du profil synthétique IA en cours…
Secteur de conventionnement non disponible (médecin hospitalier ou non présent dans l'Annuaire santé CNAM des libéraux conventionnés).
Données ANS publiques (Licence Ouverte 2.0) · Enrichissements MonRhumato 100 % opt-in · Toute personne référencée peut demander la suppression ou la rectification.
Lien Doctolib = recherche Google site:doctolib.fr (le 1er résultat est presque toujours le profil correct s'il existe).
Pharmacoepidemiology and drug safety · 2007
AbstractPurposeTo describe the characteristics of users of cyclo‐oxygenase (COX)‐2 inhibitors and traditional nonselective non‐steroidal anti‐inflammatory drugs (tNSAIDs) in France.MethodsBetween 1 August 2003 and 31 July 2004, patients who received at least one dispensing of celecoxib, rofecoxib or tNSAIDs were randomly sampled with a 1:1:2 target ratio within the French National Healthcare Insurance database. Patients and prescribers were asked to fill a questionnaire on socio‐demographic characteristics, NSAID indication and use and previous medical history. For each respondent, healthcare resources used in the 6 months before inclusion were extracted from the database. Multivariate logistic regression was used to study the determinants of a first COX‐2 inhibitor dispensing.ResultsOf the 45 217 patients included, 13 065 COX‐2 inhibitors and 13 553 tNSAID users had prescriber data. Ninety seven per cent of COX‐2 inhibitor prescriptions were for ‘rheumatological’ indications, whereas 37% of tNSAIDs use was for benign diseases (n = 2643) or analgesia (n = 2318). Among patients with rheumatological indications (n = 4730) and a first COX‐2 inhibitor (n = 2427) or tNSAID (n = 2303) dispensing, multivariate analysis of factors associated with COX‐2 inhibitors dispensing showed that, compared to new tNSAID users, new COX‐2 inhibitor users were older, more often female, on sick leave or unemployed. COX‐2 use was also associated with previous gastrointestinal history and previous gastroprotective agent dispensing, but not with previous cardiovascular (CV) history.ConclusionThe choice of NSAID depended largely on indication and on previous gastrointestinal history, in line with the recommendations of the French health authorities. Possible knowledge of CV risk associated with COX‐2 inhibitors did not influence prescribing. Copyright © 2007 John Wiley & Sons, Ltd.
British journal of clinical pharmacology · 2009
WHAT IS ALREADY KNOWN ABOUT THIS SUBJECT • To our knowledge, no study has ever described the intensity of nonsteroidal anti‐inflammatory drug (NSAID) utilization in an employed population by occupation.• As the use of NSAIDs carries a well‐known risk of adverse effects, this risk adds to the burden of musculoskeletal disorders in employed populations.• Information on utilization of NSAIDs in this context will help to better characterize and prevent this risk. WHAT THIS STUDY ADDS • In spite of a previous history of dyspepsia, blue collar workers had the highest rate of chronic and continuous utilization of nonselective NSAIDs.• No clustering of cyclooxygenase‐2 selective NSAID utilization according to a previous history of dyspepsia was observed among blue collar workers.• The association between chronicity of NSAID utilization and occupation was independent of medical indication for the prescription and other lifestyle factors.AIMThe aim of this study was to compare patterns of utilization of NSAIDs for musculoskeletal disorders (MSD) by occupation in a general employed population.METHODSThis was a secondary analysis of the CADEUS cohort study on 5651 actively employed patients, who submitted at least one claim for the reimbursement of a NSAID dispensation for a MSD between August 2003 and July 2004, in the French National Healthcare Insurance database. Questionnaires were sent to prescribing physicians to obtain diagnoses and the medical history, and to patients for their occupation, height and weight and smoking status. Multivariate logistic regression was used to study the determinants of a heavy use of NSAIDs defined as ‘over four dispensations in one year with less than two months between any two’.RESULTSFactors associated with heavy use of NSAIDs were age (Odds ratio (OR): 1.8 (ten years), 95% confidence interval (CI): 1.6–1.9), osteoarthritis (versus back pain) (OR: 1.8, 95% CI: 1.5–2.1), body mass index (superior to 30) (OR: 1.8, 95% CI: 1.5–2.2), and occupation (blue collar versus white collar workers) (OR: 1.4, 95% CI: 1.2–1.6). Blue collar workers also had a 20% higher prevalence of 5‐year history of dyspepsia. No difference was observed between sexes or in the use of COX‐2 selective inhibitors between occupations.CONCLUSIONFactors associated with occupational constraints that contribute to the severity of MSDs, may explain the heavier use of NSAIDs among blue collar workers in spite of a concurrent and past medical history of adverse reactions to this type of medication.
Source PubMed · Recherche par auteur (homonymes possibles, vérifier l'affiliation).
Pharmacoepidemiology and drug safety · 2010 · Journal Article
Fourrier-Réglat A, Cuong HM, Lassalle R, Depont F, et al.
British journal of clinical pharmacology · 2009 · Journal Article
Rossignol M, Abouelfath A, Lassalle R, Merlière Y, et al.
British journal of clinical pharmacology · 2009 · Journal Article
Rossignol M, Abouelfath A, Lassalle R, Merlière Y, et al.
Pharmacoepidemiology and drug safety · 2010 · Journal Article
Fourrier-Réglat A, Cuong HM, Lassalle R, Depont F, et al.
Pharmacoepidemiology and drug safety · 2010 · Journal Article
Fourrier-Réglat A, Cuong HM, Lassalle R, Depont F, et al.
PloS one · 2015 · Journal Article
Depont F, Berenbaum F, Filippi J, Le Maitre M, et al.
PloS one · 2015 · Journal Article
Depont F, Berenbaum F, Filippi J, Le Maitre M, et al.
Pharmacoepidemiology and drug safety · 2007 · Journal Article
Depont F, Fourrier A, Merlière Y, Droz C, et al.
Therapie · 2006 · Journal Article
Lagnaoui R, Baumevielle M, Bégaud B, Pouyanne P, et al.